{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T12:20:06Z","timestamp":1780402806240,"version":"3.54.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,12,1]],"date-time":"2015-12-01T00:00:00Z","timestamp":1448928000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"MD Anderson Cancer Center Support","award":["CA016672"],"award-info":[{"award-number":["CA016672"]}]},{"DOI":"10.13039\/100009162","name":"Hairy Cell Leukemia Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100009162","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["bprch.com","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Best Practice & Research Clinical Haematology"],"published-print":{"date-parts":[[2015,12]]},"DOI":"10.1016\/j.beha.2015.09.005","type":"journal-article","created":{"date-parts":[[2015,10,21]],"date-time":"2015-10-21T00:37:02Z","timestamp":1445387822000},"page":"230-235","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":12,"title":["Chemoimmunotherapy for hairy cell leukemia"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7621-377X","authenticated-orcid":false,"given":"Farhad","family":"Ravandi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.beha.2015.09.005_bib1","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1200\/JCO.2010.31.7016","article-title":"Modern strategies for hairy cell leukemia","volume":"29","author":"Grever","year":"2011","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.005_bib2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1056\/NEJM198401053100104","article-title":"Alpha interferon for induction of remission in hairy-cell leukemia","volume":"310","author":"Quesada","year":"1984","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.09.005_bib3","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1056\/NEJM199004193221605","article-title":"Lasting remissions in hairy-cell leukemia induced by a single infusion of 2-chlorodeoxyadenosine","volume":"322","author":"Piro","year":"1990","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.09.005_bib4","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1200\/JCO.1984.2.12.1336","article-title":"Hairy-cell leukemia: induction of complete remission with pentostatin (2'-deoxycoformycin)","volume":"2","author":"Spiers","year":"1984","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.005_bib5","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1200\/JCO.2003.05.093","article-title":"Extended follow-up of patients with hairy cell leukemia after treatment with cladribine","volume":"21","author":"Goodman","year":"2003","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.005_bib6","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1200\/JCO.1989.7.2.168","article-title":"Pentostatin in the treatment of advanced hairy cell leukemia","volume":"7","author":"Kraut","year":"1989","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.beha.2015.09.005_bib7","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1111\/j.1365-2141.2009.07668.x","article-title":"Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis","volume":"145","author":"Else","year":"2009","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2015.09.005_bib8","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1200\/JCO.1995.13.4.974","article-title":"Randomized comparison of pentostatin versus interferon alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study","volume":"13","author":"Grever","year":"1995","journal-title":"J\u00a0Clin Oncol"},{"issue":"Suppl. 2","key":"10.1016\/j.beha.2015.09.005_bib9","doi-asserted-by":"crossref","first-page":"21","DOI":"10.3109\/10428194.2011.565093","article-title":"Long-term results for pentostatin and cladribine treatment of hairy cell leukemia","volume":"52","author":"Dearden","year":"2011","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.beha.2015.09.005_bib10","doi-asserted-by":"crossref","first-page":"4788","DOI":"10.1002\/cncr.25243","article-title":"Hairy cell leukemia: evaluation of the long-term outcome in 121 patients","volume":"116","author":"Zinzani","year":"2010","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2015.09.005_bib11","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1182\/blood-2013-06-508754","article-title":"Clinical characteristics and long-term outcome of young hairy cell leukemia patients treated with cladribine: a single-institution series","volume":"123","author":"Rosenberg","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib12","doi-asserted-by":"crossref","first-page":"2305","DOI":"10.1056\/NEJMoa1014209","article-title":"BRAF mutations in hairy-cell leukemia","volume":"364","author":"Tiacci","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.beha.2015.09.005_bib13","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1182\/blood-2014-10-603100","article-title":"BRAF inhibitors reverse the unique molecular signature and phenotype of hairy cell leukemia and exert potent antileukemic activity","volume":"125","author":"Pettirossi","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib14","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1182\/blood-2010-03-276246","article-title":"Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte","volume":"116","author":"Coiffier","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib15","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1016\/S0140-6736(10)61381-5","article-title":"Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial","volume":"376","author":"Hallek","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.beha.2015.09.005_bib16","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.1182\/blood-2014-03-563627","article-title":"Improved outcome of adult Burkitt lymphoma\/leukemia with rituximab and chemotherapy: report of a large prospective multicenter trial","volume":"124","author":"Hoelzer","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib17","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1182\/blood-2008-02-140582","article-title":"Long-term results of the fludarabine, cyclophosphamide, and rituximab regimen as initial therapy of chronic lymphocytic leukemia","volume":"112","author":"Tam","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib18","first-page":"1046","article-title":"Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia","volume":"86","author":"Lauria","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.beha.2015.09.005_bib19","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1136\/jcp.51.5.364","article-title":"Levels of expression of CD19 and CD20 in chronic B cell leukaemias","volume":"51","author":"Ginaldi","year":"1998","journal-title":"J\u00a0Clin Pathol"},{"key":"10.1016\/j.beha.2015.09.005_bib20","doi-asserted-by":"crossref","first-page":"3906","DOI":"10.1182\/blood-2003-02-0630","article-title":"Rituximab in relapsed or refractory hairy cell leukemia","volume":"102","author":"Thomas","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib21","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1046\/j.1365-2141.2001.03143.x","article-title":"Rituximab, a chimaeric anti-CD20 monoclonal antibody, in the treatment of hairy cell leukaemia","volume":"115","author":"Hagberg","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.beha.2015.09.005_bib22","doi-asserted-by":"crossref","first-page":"3818","DOI":"10.1182\/blood-2011-04-351502","article-title":"Phase 2 study of cladribine followed by rituximab in patients with hairy cell leukemia","volume":"118","author":"Ravandi","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib23","doi-asserted-by":"crossref","first-page":"4658","DOI":"10.1182\/blood-2005-11-4590","article-title":"Eradication of minimal residual disease in hairy cell leukemia","volume":"107","author":"Ravandi","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib24","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1002\/cncr.23032","article-title":"The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent\/refractory hairy cell leukemia","volume":"110","author":"Else","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.beha.2015.09.005_bib25","doi-asserted-by":"crossref","first-page":"6313","DOI":"10.1158\/1078-0432.CCR-13-1848","article-title":"Bendamustine and rituximab in relapsed and refractory hairy cell leukemia","volume":"19","author":"Burotto","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.005_bib26","doi-asserted-by":"crossref","first-page":"6873","DOI":"10.1158\/1078-0432.CCR-13-1752","article-title":"Cladribine with immediate rituximab for the treatment of patients with variant hairy cell leukemia","volume":"19","author":"Kreitman","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.005_bib27","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1182\/blood-2002-04-1258","article-title":"Randomized phase 2 study of fludarabine with concurrent versus sequential treatment with rituximab in symptomatic, untreated patients with B-cell chronic lymphocytic leukemia: results from cancer and leukemia group B 9712 (CALGB 9712)","volume":"101","author":"Byrd","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib28","first-page":"1665","article-title":"Minimal residual disease in patients with hairy cell leukemia in complete remission treated with 2-chlorodeoxyadenosine or 2-deoxycoformycin and prediction of early relapse","volume":"5","author":"Tallman","year":"1999","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.beha.2015.09.005_bib29","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1182\/blood-2009-10-251645","article-title":"Very long-term eradication of minimal residual disease in patients with hairy cell leukemia after a single course of cladribine","volume":"115","author":"Sigal","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib30","doi-asserted-by":"crossref","first-page":"4687","DOI":"10.1182\/blood-2009-01-201731","article-title":"VH4-34+ hairy cell leukemia, a new variant with poor prognosis despite standard therapy","volume":"114","author":"Arons","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.beha.2015.09.005_bib31","doi-asserted-by":"crossref","first-page":"4696","DOI":"10.1182\/blood-2009-03-212449","article-title":"Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior","volume":"114","author":"Forconi","year":"2009","journal-title":"Blood"}],"container-title":["Best Practice & Research Clinical Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692615000171?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1521692615000171?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,18]],"date-time":"2018-09-18T11:20:55Z","timestamp":1537269655000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1521692615000171"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,12]]},"references-count":31,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,12]]}},"alternative-id":["S1521692615000171"],"URL":"https:\/\/doi.org\/10.1016\/j.beha.2015.09.005","relation":{},"ISSN":["1521-6926"],"issn-type":[{"value":"1521-6926","type":"print"}],"subject":[],"published":{"date-parts":[[2015,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Chemoimmunotherapy for hairy cell leukemia","name":"articletitle","label":"Article Title"},{"value":"Best Practice & Research Clinical Haematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.beha.2015.09.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}